COVID-19 RESPONSE

Click here to read about the launch of T-COVID^TM, an investigational intranasal immune modulator for the treatment of patients with early COVID-19

Click here to read about AdCOVID^TM, a single dose intranasal COVID-19 vaccine candidate, and our collaboration with the University of Alabama at Birmingham.

OUR PROGRAMS

Peptide-Based Therapeutics for Liver Diseases

Peptide-Conjugated Immunostimulants for Cancer

Intranasal vaccines for Anthrax, Influenza and COVID-19

OUR PIPELINE

Our diverse pipeline includes treatments for NASH (ALT-801), chronic Hepatitis B (HepTcell^TM), and conjugated immunostimulants for the treatment of cancer (ALT-702). In addition, we are developing intranasal vaccine programs for anthrax, influenza and COVID-19.

LIVER THERAPIES

ALT-801

HepTcell™

CANCER

ALT-702

INTRANASAL VACCINES

NasoVAX™

NasoShield™

AdCOVID™